David Hong et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(15), 1764-1771 (2016-04-06)
The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. This phase I, nonrandomized, open-label, dose-escalation trial used a 3 + 3 dose-escalation scheme and